Pesquisas alternativas:
comps » comes (Expandir a Pesquisa), combs (Expandir a Pesquisa), compr (Expandir a Pesquisa)
completed » complete (Expandir a Pesquisa)
nail » natl (Expandir a Pesquisa), neil (Expandir a Pesquisa), nair (Expandir a Pesquisa)
comer » comes (Expandir a Pesquisa), comet (Expandir a Pesquisa), homer (Expandir a Pesquisa)
comps » comes (Expandir a Pesquisa), combs (Expandir a Pesquisa), compr (Expandir a Pesquisa)
completed » complete (Expandir a Pesquisa)
nail » natl (Expandir a Pesquisa), neil (Expandir a Pesquisa), nair (Expandir a Pesquisa)
comer » comes (Expandir a Pesquisa), comet (Expandir a Pesquisa), homer (Expandir a Pesquisa)
41
Por Zahra, Amir, Fath, Melissa A., Opat, Emyleigh, Mapuskar, Kranti A., Bhatia, Sudershan K., Ma, Daniel C., Rodman, Samuel N., Snyders, Travis P., Chenard, Catherine A., Eichenberger-Gilmore, Julie M., Bodeker, Kellie L., Ahmann, Logan, Smith, Brian J., Vollstedt, Sandy A., Brown, Heather A., Hejleh, Taher Abu, Clamon, Gerald H., Berg, Daniel J., Szweda, Luke I., Spitz, Douglas R., Buatti, John M., Allen, Bryan G.
Publicado no Radiat Res (2017)
“... alone. In the phase I clinical trial, over a period of three years, seven NSCLC subjects enrolled...”Publicado no Radiat Res (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
42
Por Nichols, G, Mills, A, Grossberg, R, Lazzarin, A, Maggiolo, F, Molina, J, Pialoux, G, Wright, D, Ait-Khaled, M, Huang, J, Vavro, C, Wynne, B, Yeo, J
Publicado em 2012
“...BACKGROUND: VIKING-3 aimed to examine efficacy and safety of dolutegravir (DTG) 50 mg twice daily...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Artigo
43
Por Sheppard, John, Bergmann, Mark, Schechter, Barry A, Luchs, Jodi, Ogundele, Abayomi, Karpecki, Paul
Publicado no Clin Ophthalmol (2021)
“... results of a phase 3 worse-eye efficacy analysis and 1-year safety extension. METHODS: During the double...”Publicado no Clin Ophthalmol (2021)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
44
“... and cognitive debriefing interviews. In Phase2 participants completed postal questionnaires to assess internal...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
45
Por Massarelli, Erminia, Onn, Amir, Marom, Edith M., Alden, Christine M., Liu, Diane D., Tran, Hai T., Mino, Barbara, Wistuba, Ignacio I., Faiz, Saadia A., Bashoura, Lara, Eapen, George A., Morice, Rodolfo C., Jack Lee, J., Hong, Waun K., Herbst, Roy S., Jimenez, Carlos A.
Publicado em 2014
“...BACKGROUND: Non-small-cell lung cancer patients with malignant pleural effusion have a poor overall...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
46
Por van der Houwen, L E E, Lier, M C I, Schreurs, A M F, van Wely, M, Hompes, P G A, Cantineau, A E P, Schats, R, Lambalk, C B, Mijatovic, V
Publicado no Hum Reprod Open (2019)
“.... To demonstrate an absolute difference of 13% (delta of 10% with non-inferiority margin of 3%) with a power of 80...”Publicado no Hum Reprod Open (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
47
Por Hong, C‐H., Papp, K.A., Lophaven, K.W., Skallerup, P., Philipp, S.
Publicado no J Eur Acad Dermatol Venereol (2017)
“... received. METHODS: PSO‐INSIGHTFUL was a Phase IIIb, prospective, multicentre (Canada/Germany), open‐label...”Publicado no J Eur Acad Dermatol Venereol (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
48
Por Kunos, Charles A., Brindle, James, Waggoner, Steven, Zanotti, Kristine, Resnick, Kimberly, Fusco, Nancy, Adams, Ramon, Debernardo, Robert
Publicado em 2012
“... morbidity. We conducted a phase II study to assess the safety and the efficacy of ablative robotic...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
49
Por Jerez-Bogota, Kevin, Sánchez, Cristian, Ibagon, Jimena, Jlali, Maamer, Cozannet, Pierre, Preynat, Aurélie, Woyengo, Tofuko A
Publicado no Transl Anim Sci (2020)
Assuntos:
“...Non Ruminant Nutrition...”Publicado no Transl Anim Sci (2020)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
50
Por Hesketh, Paul J., Chansky, Kari, Wozniak, Antoinette J., Hirsch, Fred R., Spreafico, Anna, Moon, James, Mack, Philip C., Marchello, Benjamin T., Franklin, Wilbur A., Crowley, John J., Gandara, David R.
Publicado em 2008
“... daily. RESULTS: A total of 81 patients entered the study; 76 were assessable. One complete and 5 partial...”Publicado em 2008
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
51
Por Pyrhönen, S., Valavaara, R., Modig, H., Pawlicki, M., Pienkowski, T., Gundersen, S., Bauer, J., Westman, G., Lundgren, S., Blanco, G., Mella, O., Nilsson, I., Hietanen, T., Hindy, I., Vuorinen, J., Hajba, A.
Publicado em 1997
“... to receive daily either 60 mg TOR or 40 mg TAM. The patients were stratified to measurable and non-measurable...”Publicado em 1997
Obter o texto integral
Obter o texto integral
Artigo
52
Por Loprinzi, Charles L., Balcueva, Ernie P., Liu, Heshan, Sloan, Jeff A., Kottschade, Lisa A., Stella, Philip J., Carlson, Mark D., Moore, Dennis F., Zon, Robin T., Levitt, Ralph, Jaslowski, Anthony J.
Publicado em 2011
“...PURPOSE: Vaginal dryness is a common problem, for which effective and safe non-estrogenic...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
53
Por Holloway, Cassie L, Boyd, R Dean, Koehler, Dean, Gould, Stacie A, Li, Qingyun, Patience, John F
Publicado no Transl Anim Sci (2018)
Assuntos:
“...Non Ruminant Nutrition...”Publicado no Transl Anim Sci (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
54
Por Weekes, Colin D., Nallapareddy, Sujatha, Rudek, Michelle A., Norris-Kirby, Alexis, Laheru, Daniel, Jimeno, Antonio, Donehower, Ross C., Murphy, Kathleen M., Hidalgo, Manuel, Baker, Sharyn D., Messersmith, Wells A.
Publicado em 2010
“... 3 non-hematologic toxicities of palmer-plantar erythrodysesthesia, diarrhea, nausea and vomiting...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
55
Por Verschuur, Arnauld C., Bajčiová, Viera, Mascarenhas, Leo, Khosravan, Reza, Lin, Xun, Ingrosso, Antonella, Janeway, Katherine A.
Publicado no Cancer Chemother Pharmacol (2019)
“... completed at least three treatment cycles, with one completing all 18 cycles. Five patients had a dose...”Publicado no Cancer Chemother Pharmacol (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
56
Por Z. A.-G. Radzhabova, M. A. Kotov, Z. S. Bekyasheva, M. A. Radzhabova, E. V. Levchenko
Publicado em 2020-02-01
“... who participated in a multicenter, non-randomized clinical trial of phase II ERIVANCE BBC...”Publicado em 2020-02-01
Obter o texto integral
Artigo
57
Por Robison, Nathan J, Campigotto, Federico, Chi, Susan N, Manley, Peter E, Turner, Christopher D, Zimmerman, Mary Ann, Chordas, Christine A, Werger, Annette M, Allen, Jeffrey C, Goldman, Stewart, Rubin, Joshua B, Isakoff, Michael S, Pan, Wilbur J, Khatib, Ziad A, Comito, Melanie A, Bendel, Anne E, Pietrantonio, Jay B, Kondrat, Laura, Hubbs, Shannon M, Neuberg, Donna S, Kieran, Mark W
Publicado no Pediatr Blood Cancer (2014)
“..., single-arm, multi-institutional phase II study to evaluate the efficacy of a “5-drug” oral regimen...”Publicado no Pediatr Blood Cancer (2014)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
58
Por Young, Patricia A, Marquez-Garban, Diana C, Goodglick, Lee, Noor, Zorawar S, Moatamed, Neda, Elashoff, David, Grogan, Tristan, Romero, Tahmineh, Sasano, Hironobu, Saito, Ryoko, Rausch, Rebecca, Hamilton, Nalo, Dubinett, Steven M, Garon, Edward, Pietras, Richard J
Publicado no J Endocr Soc (2020)
“... (Cohort 1) or 50 mg PO daily (Cohort 2) with carboplatin (AUC 6 mg x min/mL) and pemetrexed (500 mg/m2) IV...”Publicado no J Endocr Soc (2020)
Obter o texto integral
Obter o texto integral
Artigo
59
Por McKay, Rana R., Werner, Lillian, Mostaghel, Elahe A., Lis, Rosina, Voznesensky, Olga, Zhang, Zhenwei, Marck, Brett T., Matsumoto, Alvin M., Domachevsky, Liran, Zukotynski, Katherine A., Bhasin, Manoj, Bubley, Glenn J., Montgomery, Bruce, Kantoff, Philip W., Balk, Steven P., Taplin, Mary-Ellen
Publicado no Clin Cancer Res (2016)
“... (3.5mg daily) was added. Patients continued therapy until study withdrawal or radiographic progression...”Publicado no Clin Cancer Res (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
60
Por Moreno-González, G., Mussetti, A., Albasanz-Puig, A., Salvador, I., Sureda, A., Gudiol, C., Salazar, R., Marin, M., Garcia, M., Navarro, V., de la Haba Vaca, I., Coma, E., Sanz-Linares, G., Dura, X., Fontanals, S., Serrano, G., Cruz, C., Mañez, R.
Publicado no Trials (2021)
“... phase I/II study with a safety run-in cohort (phase 1) followed by an open label phase II randomized...”Publicado no Trials (2021)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo